Objective: To determine the natural history of treated and untreated eosinophilic esophagitis (EE) and examine the presenting symptoms of EE.
Patients And Methods: Retrospective and prospective chart review of all patients diagnosed with EE at The Children's Hospital of Philadelphia. EE was defined as greater than 20 eosinophils per high power field after treatment with reflux medications.
Results: We identified 620 patients in our database in the last 14 years and 330 patients with greater than 1 year of follow-up for analysis. The number of new EE patients has increased on an annual basis. Of the patients presenting with EE, 68% were younger than 6 years old. Reflux symptoms and feeding issues/failure to thrive were the most common presenting symptoms for EE. Eleven patients had resolution of all of their food allergies and 33 patients had resolutions of some of their food allergies. No patients have progression of EE into other gastrointestinal disorders.
Conclusions: EE is a chronic disease with less than 10% of the population developing tolerance to their food allergies. EE does not progress into other gastrointestinal diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPG.0b013e3181788282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New approaches in childhood IgE-mediated food allergy treatment.
Curr Opin Allergy Clin Immunol
January 2025
Translational Research in Pediatric Specialities, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Purpose Of Review: This review aims to provide an overview of the current and future treatment options for children with food allergies (FAs), highlighting the latest research findings and the potential impact of these new approaches on improving patients' and caregivers' quality of life.
Recent Findings: In the last decade, many promising approaches have emerged as an alternative to the standard avoidance of the culprit food with the risk of severe accidental reactions. Desensitization through oral immunotherapy has been introduced in clinical settings as a therapeutic approach, and more recently also omalizumab.
Diversity of complementary diet and early food allergy risk.
Pediatr Allergy Immunol
January 2025
Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.
Introduction: Diet diversity (DD) in infancy may be protective for early food allergy (FA) but there is limited knowledge about how DD incorporating consumption frequency influences FA risk.
Methods: Three measures of DD were investigated in 2060 infants at 6 and/or at 9 months of age within the NorthPop Birth Cohort Study: a weighted DD score based on intake frequency, the number of introduced foods, and the number of introduced allergenic foods. In multivariable logistic regression models based on directed acyclic graphs, associations to parentally reported physician-diagnosed FA at age 9 and 18 months were estimated, including sensitivity and stratified analyses.
Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.
EClinicalMedicine
February 2025
Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany.
Unlabelled: Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases.
View Article and Find Full Text PDFComparison of the new RIDA qLine Allergy multiparameter immunoblot and the ImmunoCAP Specific IgE test for the identification of clinically relevant food and aeroallergen allergies.
Front Allergy
January 2025
Department of Dermatology, Venereology and Allergology, University Medical Centre Goettingen, Goettingen, Germany.
Background: Multiparameter immunoblot testing is increasingly used as an alternative to multiple individual IgE analyses for type 1 allergies. This study investigated the performance of an inexpensive immunoblot method, the RIDA qLine allergy test system (R-Biopharm AG), vs. the current gold standard.
View Article and Find Full Text PDFEvaluation of bone development and organs in rat fetuses exposed to tartrazine.
Heliyon
January 2025
Yozgat Bozok University, Faculty of Medicine, Department of Anatomy, Yozgat, Turkey.
Tartrazine finds widespread application in the realms of alimentation, pharmaceuticals, cosmetic formulations, and textile manufacturing. Tartrazine has a negative effect on human health such as hyperactivity, allergies and asthma in children. Substances such as tartrazine might effect the embryo in a kind of aspects, containing physical or mental disorders, and a decrease in the child's intellectual memory.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!